Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed glioblastoma

- Measurable disease by MRI

- Completed standard first-line treatment for glioblastoma including surgery (unless
not received due to anatomical location), radiotherapy and temozolomide (last dose
given at least 28 days prior to enrollment)

- No other prior treatment for glioblastoma except Gliadel or steroids

- Recurrent or progressive disease after standard first-line treatment

- No disease progression within 3 months of completion of radiotherapy

- No intra- or peri-tumoral hemorrhage

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Mini-mental status score ≥ 15

- Life expectancy ≥ 12 weeks

- Serum bilirubin, ALT/AST, creatinine, and urine protein normal

- Adequate bone marrow reserve

- Not pregnant or nursing

- Normal ECG

- No history of familial long QT syndrome

- No absorption or swallowing difficulties

- No uncontrolled hypertension or cardiac ventricular arrhythmias

- No current or history of uncontrolled hypertension or requiring maximal doses of
calcium channel blockers

- No severe or uncontrolled disease

- No history of lung disease

- No recent hemorrhage or hemoptysis

- No known hypersensitivity to cediranib maleate, gefitinib, or any excipients

- No history of other malignancies except adequately treated basal cell or squamous
cell carcinoma or carcinoma in situ within the past 5 years, unless disease-free for
2 years with tissue diagnosis

- No known HIV positivity

- No known hepatitis B or C infection

- No unhealed surgical incision

- Not involved in planning or conducting this study

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior anticancer therapy, including radiotherapy

- At least 3 months since prior cranial radiation

- At least 30 days since prior investigational drugs

- At least 28 days since prior craniotomy

- At least 2 weeks since prior enzyme-inducing antiepileptic drugs

- At least 2 weeks since prior and no concurrent dexamethasone (> 8 mg/day) or
equivalent

- At least 14 days since prior major surgery or brain biopsy

- No concurrent steroids OR on stable dose 5 days prior to baseline MRI

- No other concurrent anticancer therapy, except for steroids (dexamethasone only)

- No previous enrollment on the current study

- No prior inhibitors of angiogenesis, EGFR, or downstream targets

- No prior radiosurgery or brachytherapy